A case of Guillian-Barre syndrome following COVID-19 vaccination

This case is noteworthy due the association between the COVID-19 vaccination and GBS. This patient developed symptoms of GBS approximately a week after his COVID-19 vaccination. This was determined by his neurologist after a further history. Therefore, GBS should be considered as a possible side effect to the COVID-19 vaccination.

Content

Author and article information

Journal

Title: ScienceOpen Preprints

Publisher: ScienceOpen

Publication date (Electronic preprint): 22 August 2024

Affiliations

[1 ] Kansas City university;

Author notes

[* ]Email: meshusingh@ 123456kansascity.edu .

Author information

Maneesh Singh https://orcid.org/0000-0003-4859-2546

Article

DOI: 10.14293/PR2199.001008.v1

SO-VID: 5c798967-f66e-4451-b19c-c92f4cb1f853

License:

This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

History

Date received : 22 August 2024

References

Shahrizaila Nortina, Lehmann Helmar C, Kuwabara Satoshi. Guillain-Barré syndrome. The Lancet. Vol. 397(10280):1214–1228. 2021. Elsevier BV. [Cross Ref]
Yao Jiajia, Zhou Rumeng, Liu Yue, Lu Zuneng. Progress in Guillain–Barré syndrome immunotherapy—A narrative review of new strategies in recent years. Human Vaccines & Immunotherapeutics. Vol. 19(2)2023. Informa UK Limited. [Cross Ref]
Leonhard Sonja E., Mandarakas Melissa R., Gondim Francisco A. A., Bateman Kathleen, Ferreira Maria L. B., Cornblath David R., van Doorn Pieter A., Dourado Mario E., Hughes Richard A. C., Islam Badrul, Kusunoki Susumu, Pardo Carlos A., Reisin Ricardo, Sejvar James J., Shahrizaila Nortina, Soares Cristiane, Umapathi Thirugnanam, Wang Yuzhong, Yiu Eppie M., Willison Hugh J., Jacobs Bart C.. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nature Reviews Neurology. Vol. 15(11):671–683. 2019. Springer Science and Business Media LLC. [Cross Ref]

Comments

Comment on this article

[1] Shahrizaila Nortina, Lehmann Helmar C, Kuwabara Satoshi. Guillain-Barré syndrome. The Lancet. Vol. 397(10280):1214–1228. 2021. Elsevier BV. [Cross Ref]

[2] Yao Jiajia, Zhou Rumeng, Liu Yue, Lu Zuneng. Progress in Guillain–Barré syndrome immunotherapy—A narrative review of new strategies in recent years. Human Vaccines & Immunotherapeutics. Vol. 19(2)2023. Informa UK Limited. [Cross Ref]

[3] Leonhard Sonja E., Mandarakas Melissa R., Gondim Francisco A. A., Bateman Kathleen, Ferreira Maria L. B., Cornblath David R., van Doorn Pieter A., Dourado Mario E., Hughes Richard A. C., Islam Badrul, Kusunoki Susumu, Pardo Carlos A., Reisin Ricardo, Sejvar James J., Shahrizaila Nortina, Soares Cristiane, Umapathi Thirugnanam, Wang Yuzhong, Yiu Eppie M., Willison Hugh J., Jacobs Bart C.. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nature Reviews Neurology. Vol. 15(11):671–683. 2019. Springer Science and Business Media LLC. [Cross Ref]

Share your research early and openly – submit your preprint to ScienceOpen today! See how it works in the video!